By Cheryl Selleny, Marketing and Communications
The 6th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference is taking place in sunny San Diego from November 14-16. The conference will cover every stage of clinical trials in AD and provide an opportunity for industry leaders to share innovative research with their peers.
See below for a list of our subject matter experts’ presentations taking place during the conference.
The poster presentations will be displayed throughout the conference.
P4: Selecting Acceptable Caregiver Informants for AD Clinical Trials: Is More Care Needed?
Priscilla Samuelson, RN and David S. Miller, MD, MA
Thursday, November 14th
9:15 – 10:30am
Clinical trials in early stage Alzheimer’s disease: Current methodological and regulatory considerations
Moderator: John Harrison PhD, Metis Cognition Ltd, Kilmington Common, Wiltshire, UK
- What are we trying to measure in preclinical and prodromal Alzheimer’s disease?
Lon Schneider MD, MS. Keck School of Medicine of the University of Southern California, USA
- How can changes in cognitive function be measured in therapeutic trials in preclinical AD?
Keith Wesnes PhD, Bracket Global, Goring UK & Swinburne University, Melbourne, Australia
- A regulatory perspective on therapeutic trials in early stage Alzheimer’s disease
Nicholas Kozauer MD, Food and Drug Administration, Silver Spring, MD, USA
California Ballroom AB: Data from Clinical Trials
11:15 – 11:30am
OC 2: Improvements to attention and verbal episodic memory with memantine in Parkinson’s disease dementia and dementia with Lewy bodies
Keith A. Wesnes, Dag Aarsland, Clive Ballard, Elisabet Londos
12:15 – 12:30pm
OC6: Evidence that compromised neurogenesis in Alzheimer’s disease is linked to APOE ϵ4 status and CSF Aß42
Keith A. Wesnes PhD, Peter Annas PhD, Hans Basun MD PhD, Kaj Blennow MD PhD
Friday, November 15th
Ballroom C: Treatment Assessment for Clinical Trials
2:00 – 2:15 pm
OC39: Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12 week study
K. Wesnes, J.O. Rinne, J. Hänninen, M. Murphy, H. Riordan, J. Rouru, and the ALPO Study Group